Vericel (NASDAQ:VCEL – Get Rating) will release its earnings data before the market opens on Wednesday, May 4th. Analysts expect Vericel to post earnings of ($0.15) per share for the quarter. Vericel has set its FY 2022 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.
Vericel (NASDAQ:VCEL – Get Rating) last announced its earnings results on Thursday, February 24th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.08). Vericel had a negative net margin of 4.78% and a negative return on equity of 4.83%. The business had revenue of $47.60 million for the quarter, compared to analysts’ expectations of $48.09 million. During the same period in the prior year, the business earned $0.25 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of Vericel stock opened at $32.62 on Wednesday. Vericel has a 1 year low of $30.67 and a 1 year high of $68.94. The firm has a market cap of $1.53 billion, a PE ratio of -191.88 and a beta of 1.87. The stock has a fifty day moving average price of $36.69 and a 200-day moving average price of $39.09.
VCEL has been the subject of several research reports. SVB Leerink increased their price target on Vericel from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. StockNews.com initiated coverage on shares of Vericel in a report on Thursday, March 31st. They set a “sell” rating on the stock. TheStreet cut shares of Vericel from a “c-” rating to a “d+” rating in a research report on Thursday, March 31st. Finally, Zacks Investment Research cut shares of Vericel from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 12th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $54.00.
About Vericel (Get Rating)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.